Higher Throughput Behavioral Screening of Cognitive Enhancers

Information

  • Research Project
  • 7169555
  • ApplicationId
    7169555
  • Core Project Number
    R43MH076342
  • Full Project Number
    5R43MH076342-02
  • Serial Number
    76342
  • FOA Number
    PA-04-86
  • Sub Project Id
  • Project Start Date
    1/15/2006 - 18 years ago
  • Project End Date
    12/31/2007 - 16 years ago
  • Program Officer Name
    GRABB, MARGARET C.
  • Budget Start Date
    1/25/2007 - 17 years ago
  • Budget End Date
    12/31/2007 - 16 years ago
  • Fiscal Year
    2007
  • Support Year
    2
  • Suffix
  • Award Notice Date
    1/24/2007 - 17 years ago
Organizations

Higher Throughput Behavioral Screening of Cognitive Enhancers

[unreadable] DESCRIPTION (provided by applicant): This application is submitted in response to NIMH research topic J1, neuroscience and basic behavioral science in the SBIR solicitation and PA-04-086, development of high throughput tools for brain and behavior. We aim to alleviate the bottleneck in drug discovery for cognitive dysfunction with CognoCube(tm), an automated high-throughput system of behavioral analysis of cognitive function. CognoCube(tm) will comprise innovative automated testing, computer vision, and machine-learning algorithms to capture and integrate behavioral effects of drugs affecting cognitive function. CognoCube will capture many cognitive domains of high degree of homology between humans and rodents that are relevant in CNS disorders such as schizophrenia, dementia, attention-deficit disorder and ageing. This system will provide rapid and accurate indices of the therapeutic potential of novel cognitive enhancers. Phase I will be focused on proof of concept, namely, capture of behaviors relevant to targeted cognitive domains, sensitivity to pharmacological manipulation and robust bioinformatic analysis. The CognoCube(tm) system will expand its capacity during Phase II of the project to be able to assess a library of 1000 compounds per year. With libraries chosen to provide a high likelihood of CNS activity we expect to be able to detect up to a dozen new compounds per year with CNS activity in the area of cognition. Those compounds will be further assessed with standard tests of cognition and their mechanism of action will be studied through pharmacological means and binding profiling. Commercial value: The population that could benefit from new and improved cognitive enhancers is estimated at more than 30 million in the United States alone. Major challenges for drug discovery in this area include the lack of reliable and efficient in vivo testing systems. Although standardized objective test batteries have been developed for evaluation of human cognition, there is no such standard battery for rodents. Our automated cognitive testing system for mice will provide superior reliability, greater statistical power and higher throughput than standard cognitive tests and, with its power to screen libraries in vivo, will discover novel compounds with efficacy in cognition. [unreadable] [unreadable]

IC Name
NATIONAL INSTITUTE OF MENTAL HEALTH
  • Activity
    R43
  • Administering IC
    MH
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    199963
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    242
  • Ed Inst. Type
  • Funding ICs
    NIMH:199963\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    PSYCHOGENICS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    TARRYTOWN
  • Organization State
    NY
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    10591
  • Organization District
    UNITED STATES